Vertical: Healthcare
Market Size (2019)
$2.94B
Projected (2036)
$21.91B
CAGR (2019–2036)
12.5%
Key Players
10+
This report covers North America & Europe Immuno-Therapy Market with forecasts from 2019 to 2036. 10 key companies are profiled.
The North America & Europe Immuno-Therapy Market market is projected to grow at a CAGR of 12.5% from 2019 to 2036.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe immunotherapy market in North America and Europe stands at the forefront of transformative healthcare innovation, driven by a confluence of escalating clinical needs and technological breakthroughs that are reshaping treatment paradigms for immune- mediated disorders. In these regions, the rising prevalence of allergic rhinitis and allergic asthma has intensified demand, as environmental factors, urbanization, and lifestyle shifts amplify the burden on healthcare systems, compelling a shift toward targeted immunotherapies that address root causes rather than mere symptom palliation. This momentum is further propelled by advancements in biotechnology, where cutting-edge techniques like precision gene editing and biologics engineering enable more effective, personalized interventions, fostering a landscape ripe for sustained growth. Bolstering this trajectory are increasing research and development investments from pharmaceutical giants, academic institutions, and public-private partnerships, which channel resources into novel delivery mechanisms and combination therapies, accelerating the pipeline from bench to bedside. Concurrently, growing pediatric adoption reflects heightened awareness among clinicians and parents of immunotherapy's long-term benefits, such as disease modification and reduced reliance on daily medications, expanding the addressable patient pool across age demographics. Yet, these opportunities are tempered by notable restraints.
High treatment costs, stemming from complex manufacturing and cold- chain logistics, pose affordability challenges, particularly for uninsured or underinsured populations. Limited patient accessibility exacerbates this, with geographic disparities in specialized care centers and long wait times hindering equitable rollout. Regulatory hurdles, including stringent approval pathways and post-market surveillance requirements from bodies like the FDA and EMA, further slow market penetration despite robust safety profiles. Amid these dynamics, significant opportunities emerge through the advent of emerging novel therapeutics, such as next-generation biologics and microbiome-modulating agents, poised to capture unmet needs. The expansion of clinical trials, leveraging decentralized models and real-world evidence, promises to validate efficacy in diverse cohorts, unlocking broader reimbursement and adoption. Overall, the North America and Europe immunotherapy market embodies a delicate balance of innovation-driven expansion and structural challenges, positioning it for resilient evolution as stakeholders navigate costs, access, and regulation to harness immunotherapy's full potential.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
—
Historical Period
2019 – 2036
Forecast Period
2019 – 2036
Primary Interviews
150+
Historical performance and future projections
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Market estimates by geography (2036)
InsightNorth America (in USD Mn) leads with $15.03B by 2036, while Dupilumab is projected to grow fastest at a 16.8% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2019 | 2036 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America (in USD Mn) | $1.96B | $8.39B | $15.03B | 12.7% | 26% |
| North America | $1.96B | $8.39B | $15.03B | 12.7% | 26% |
| Dupilumab | $412.00M | $2.92B | $5.77B | 16.8% | 10% |
| U.S. (in USD Mn) | $1.91B | $8.17B | $14.38B | 12.6% | 25% |
| Canada (in USD Mn) | $51.60M | $219.10M | $650.60M | 16.1% | 1% |
| Europe (in USD Mn) | $976.30M | $3.38B | $6.88B | 12.2% | 12% |
| Total | $8.98B | $37.52B | $57.75B | 12.5% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on North America & Europe Immuno-Therapy Market covering market dynamics, competitive landscape, and strategic outlook.
The North America & Europe Immuno-Therapy Market market is projected to reach $21.91B by 2036, growing at 12.5% CAGR.
The immunotherapy market in North America and Europe stands at the forefront of transformative healthcare innovation, driven by a confluence of escalating clinical needs and technological breakthroughs that are reshaping treatment paradigms for immune- mediated disorders. In these regions, the rising prevalence of allergic rhinitis and allergic asthma has intensified demand, as environmental factors, urbanization, and lifestyle shifts amplify the burden on healthcare systems, compelling a shift toward targeted immunotherapies that address root causes rather than mere symptom palliation. This momentum is further propelled by advancements in biotechnology, where cutting-edge techniques like precision gene editing and biologics engineering enable more effective, personalized interventions, fostering a landscape ripe for sustained growth. Bolstering this trajectory are increasing research and development investments from pharmaceutical giants, academic institutions, and public-private partnerships, which channel resources into novel delivery mechanisms and combination therapies, accelerating the pipeline from bench to bedside. Concurrently, growing pediatric adoption reflects heightened awareness among clinicians and parents of immunotherapy's long-term benefits, such as disease modification and reduced reliance on daily medications, expanding the addressable patient pool across age demographics. Yet, these opportunities are tempered by notable restraints.
High treatment costs, stemming from complex manufacturing and cold- chain logistics, pose affordability challenges, particularly for uninsured or underinsured populations. Limited patient accessibility exacerbates this, with geographic disparities in specialized care centers and long wait times hindering equitable rollout. Regulatory hurdles, including stringent approval pathways and post-market surveillance requirements from bodies like the FDA and EMA, further slow market penetration despite robust safety profiles. Amid these dynamics, significant opportunities emerge through the advent of emerging novel therapeutics, such as next-generation biologics and microbiome-modulating agents, poised to capture unmet needs. The expansion of clinical trials, leveraging decentralized models and real-world evidence, promises to validate efficacy in diverse cohorts, unlocking broader reimbursement and adoption. Overall, the North America and Europe immunotherapy market embodies a delicate balance of innovation-driven expansion and structural challenges, positioning it for resilient evolution as stakeholders navigate costs, access, and regulation to harness immunotherapy's full potential.
Rising Prevalence of Allergic Rhinitis & Allergic Asthma in NA & EU
The increasing burden of allergic respiratory conditions across North America and Europe represents a fundamental demand driver for immunotherapy interventions. According to the U.S. Centers for Disease Control and Prevention's National Health Interview Survey (NHIS) 2021 data, 25.7% of American adults (approximately 66 million individuals) reported diagnosed seasonal Allergies, which include hay fever, allergic rhinitis, and allergic conjunctivitis. Among children aged 0–17 years, 18.9% had seasonal Allergies, affecting roughly 14 million pediatric patients. The CDC further reports that approximately 65.9% of children with asthma have comorbid allergic conditions, creating substantial overlap populations requiring targeted immunotherapy approaches.
In Europe, the burden remains equally significant. A comprehensive 2018 National Health and Wellness Survey across five major European markets (France, Germany, Italy, Spain, and the United Kingdom) documented an asthma prevalence of 6.7% among adults, with the UK reporting the highest rates at 10.4%. Notably, 52.0% of diagnosed asthma patients rated their condition as mild, 27.9% as moderate, and 20.1% as severe indicating substantial unmet medical need among moderate-to-severe patients who represent the primary candidates for biologic immunotherapy. The CDC's longitudinal surveillance confirms asthma prevalence among American adults increased significantly from 2013 through 2021, with 8.0% of adults (20.3 million) reporting current asthma in 2021, while children maintained a 6.5% prevalence rate. These epidemiological trends, combined with documented healthcare utilization disparities and persistent uncontrolled symptoms in approximately 50% of pediatric and 62% of adult asthma patients, create sustained market demand for disease-modifying immunotherapy interventions that address underlying Type 2 inflammation rather than merely controlling symptoms.
Advancements in Biotechnology
The immunotherapy market has been fundamentally transformed by breakthrough biotechnology innovations, particularly in monoclonal antibody engineering and manufacturing capabilities. The industry has entered what researchers characterize as "Era 4" of therapeutic antibody development (2024+), characterized by production culture titers exceeding 8 g/L and maximum single-product manufacturing volumes surpassing 10 tons annually, a tenfold increase from capacity levels just five years prior. These manufacturing advances have direct implications for the accessibility and cost structures of immunotherapy, enabling broader patient populations to access previously supply-constrained biologics.
The FDA's approval data demonstrates unprecedented momentum in biologic immunotherapy development. From January 2023 through October 2024, the agency approved 16 first-in-class macromolecular drugs, with antibody drugs representing the dominant modality. Notably, 8 first-in-class antibody/ADC drugs received approval during this 22-month period—comparable to the entire 2019–2022 approval volume and substantially exceeding the 2011–2014 period. Specific immunotherapy breakthroughs include the FDA's December 2021 approval of Tezepelumab (Tezspire), the first biologic targeting thymic stromal lymphopoietin (TSLP) for severe asthma without phenotype or biomarker limitations, representing a paradigm shift toward precision immunotherapy.
Manufacturing technology advances have enabled production scalability that supports market expansion. The U.S. Department of Health and Human Services announced in 2023 a multi-year initiative to bolster domestic manufacturing capabilities for monoclonal antibodies, ensuring supply chain resilience. Johnson & Johnson's June 2024 expansion of biologics manufacturing capacity in Pennsylvania, representing an investment exceeding $500 million, exemplifies the industry's commitment to scaling immunotherapy production. These infrastructure investments, combined with process innovations such as single-use bioreactors and continuous manufacturing platforms, have reduced the cost-of-goods and enabled the commercial viability of next-generation immunotherapies targeting smaller patient populations.
Increasing Research and Development Investment
Pharmaceutical and biotechnology companies have substantially increased R&D commitments to immunotherapy programs, reflecting confidence in the therapeutic modality's commercial potential and clinical value proposition. Regeneron Pharmaceuticals, developer of the blockbuster immunotherapy dupilumab (Dupixent), invested $4.4 billion in R&D during 2023, representing 34% of total revenue. This investment intensity continued into 2024, with Q4 2024 R&D expenses reaching $1.412 billion, a 20% year-over-year increase driven by mid- and late-stage clinical pipeline advancement. The company's 2023 Responsibility Report explicitly identifies immunology and inflammation as core therapeutic focus areas, with ongoing programs targeting grass and birch pollen Allergies in Phase 3 development. At the industry level, the European Federation of Pharmaceutical Industries and Associations (EFPIA) documented that the research-based pharmaceutical industry invested approximately €50 billion in R&D across Europe in 2023. This investment occurs within a competitive landscape where North America captured 53.3% of world pharmaceutical sales, with 67.1% of new medicines launched during 2018–2023 first reaching the U.S. market, indicating North America's central role in immunotherapy commercialization.
AstraZeneca's 2023 Annual Report illustrates strategic prioritization of immunotherapy expansion, with the company completing more than 60 major business development transactions over three years, including the November 2023 exclusive license agreement for AZD5004 involving $185 million upfront and up to $1.81 billion in future milestones. The investment trajectory extends beyond established players to specialized biotechnology firms. Eli Lilly committed nearly $1.0 billion in March 2023 for a monoclonal antibody manufacturing facility in Ireland, targeting novel clinical treatment production by 2026. This capital deployment reflects expectations of sustained immunotherapy demand growth and the need for manufacturing capacity to support pipeline assets. The aggregate R&D investment patterns demonstrate industry consensus that immunotherapy represents a high-value therapeutic category warranting substantial resource allocation.
Increasing Pediatric Adoption
The expansion of immunotherapy indications into pediatric populations represents a significant market growth driver, supported by regulatory approvals and evolving treatment paradigms. The FDA's June 2022 approval of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis marked a watershed moment as the first systemic treatment (and only biologic) approved for this age group. This approval was based on the LIBERTY AD PRESCHOOL trial, which demonstrated that by week 52 of open-label extension treatment, 96.6% of pediatric patients achieved at least 50% improvement in Eczema Area and Severity Index scores, with 36.2% achieving clear or almost clear skin. The pediatric immunotherapy landscape has expanded rapidly across multiple indications. In October 2021, the FDA approved dupilumab for children aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or oral corticosteroid dependence. Omalizumab's indication was expanded to include children aged 6–11 years in 2016, with utilization data showing a 58 per 100,000 children increase in Medicaid populations and 57 per 100,000 in commercial insurance following FDA approval, demonstrating immediate post-approval adoption.
Emerging Novel Therapeutics
The immunotherapy landscape is experiencing unprecedented innovation with the emergence of first-in-class biologics targeting novel pathways, creating substantial market expansion opportunities. The FDA's approval of nemolizumab (Nemluvio) on December 13, 2024, represents a paradigm shift as the first monoclonal antibody specifically targeting the IL-31 receptor α, inhibiting signaling of IL-31, a neuroimmune cytokine that drives itch and inflammation in atopic dermatitis. This approval followed the drug's initial approval for prurigo nodularis in August 2024, demonstrating rapid indication expansion. Nemolizumab's distinct mechanism addresses the "unbearable itching" that disrupts sleep and quality of life, with clinical trials showing dramatic improvements in itch scores often within days of treatment initiation. The TSLP inhibitor pipeline has intensified competition following tezepelumab's success. At least 20 distinct TSLP-targeting molecules currently exist in clinical development, with next-generation approaches showing superior potency. Verekitug (Upstream Bio), a novel TSLP receptor antibody, demonstrated 15-fold greater potency than tezepelumab in inhibiting receptor dimerization and maintained TSLP receptor inhibition for up to 24 weeks after the last dose, potentially enabling less frequent dosing.
Solrikitug (Uniquity Bio) received up to USD 300 million in funding from Blackstone in May 2024 to initiate Phase II trials in COPD and asthma, while Lunsekimig (Sanofi) represents an innovative bispecific approach combining TSLP inhibition with IL-13 blockade in a single molecule. The IL-33/ST2 axis has emerged as a critical therapeutic target, with itepekimab (Regeneron), tozorakimab (AstraZeneca), and astegolimab (Genentech) advancing through clinical development. These alarmins (TSLP and IL-33) initiate and maintain type 2 immune responses, offering broader therapeutic potential than downstream cytokine targeting. The development of inhalable nanobodies targeting TSLP, as described in 2025 preclinical studies, represents a novel delivery approach that could expand patient acceptance and compliance.
Expansion of Clinical Trials
Clinical trial activity for immunotherapy has expanded significantly, driven by regulatory mandates and scientific advancement. The FDA's Food and Drug Omnibus Reform Act of 2022 (FDORA), enacted December 29, 2022, granted the agency statutory authority to require drug sponsors to submit Diversity Action Plans (DAPs) specifying enrollment goals by race, ethnicity, sex, and age. The FDA published revised draft guidance on DAP format and content on June 26, 2024, with requirements applying to studies enrolling after 180 days from final guidance publication. This regulatory framework ensures broader demographic representation, enhancing the generalizability of immunotherapy efficacy data across diverse populations.
The OUtMATCH trial (Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults), conducted at 10 locations across the United States, exemplifies large-scale immunotherapy research infrastructure expansion. This NIH-funded study enrolled 177 children and adolescents ages 1 to 17 years and three adults, with findings published in The New England Journal of Medicine in 2024, leading to FDA approval. Stage 3 results presented in 2025 demonstrated that patients may introduce allergenic foods into their diets after curtailing omalizumab, suggesting potential for treatment modification rather than indefinite therapy.
Long-term safety studies are expanding to support chronic immunotherapy use. An ongoing 200-week Phase 3 clinical trial assessing nemolizumab in adolescents and adults (ages ≥12) with moderate-to-severe atopic dermatitis aims to recruit 1,700 participants, with estimated completion in August 2026. This extended follow-up addresses the need for long-term safety data required for chronic biologic therapy approval and reimbursement. The expansion of clinical trial networks into community settings, rather than solely academic medical centers, increases patient access to investigational therapies and accelerates enrollment timelines.
High Treatment Costs
The economic burden of biologic immunotherapy represents a fundamental barrier to market expansion, with annual therapy costs creating substantial accessibility challenges for patients and healthcare systems. According to the Canadian Agency for Drugs and Technologies in Health (CADTH), dupilumab (Dupixent) annual treatment costs range from $12,723 to $25,446 depending on dosing regimen (200 mg every 2 weeks versus 300 mg every 4 weeks), with a per-prefilled syringe price of $978.70. U.S. market data indicates even higher costs, with DrugPatentWatch reporting annual therapy expenses approximating $35,000 to $40,000 per patient, while European list prices remain 20-30% lower due to healthcare policy variations.
Omalizumab (Xolair) demonstrates similar cost variability based on dosing requirements. The Canadian pharmacoeconomic review documented annual costs ranging from $7,956 to $47,736, depending on patient weight and IgE levels, with individual vial pricing at $612. These costs are particularly burdensome given that biologics require indefinite maintenance therapy rather than finite treatment courses. The economic evaluation noted that at the submitted price, omalizumab was not cost-effective according to Canadian Expert Drug Advisory Committee assessments, with incremental cost-effectiveness ratios ranging from $35,000 to $219,000 per quality-adjusted life-year (QALY). The cost barrier extends beyond direct drug pricing to include healthcare system infrastructure requirements. The CDC's 2023 analysis of Medicaid coverage documented those monoclonal antibodies, estimated to cost $30,000-$40,000 per patient per annum, contribute to high asthma treatment costs, driving payer restrictions that limit access. These economic constraints disproportionately impact publicly insured patients, who bear a disproportionate burden of uncontrolled asthma yet face greater restrictions in accessing biologic therapies.
Limited Patient Accessibility
Structural barriers to immunotherapy access create significant market constraints, with insurance coverage limitations, specialist availability, and geographic disparities restricting patient reach. The American Lung Association's comprehensive 2021–2022 analysis of all 50 state Medicaid programs, the District of Columbia, and Puerto Rico documented systematic barriers across all categories of asthma care. For controller medications (including biologics), prior authorization was required in 98.1% of Medicaid programs, quantity limits existed in 86.5%, and step therapy requirements were present in 88.5% of programs. These administrative barriers create substantial delays in research from the University of Pennsylvania, documenting a median of 32.5 days and a mean of 57.8 days from biologic prescription to first administration, with patient-level barriers (loss to follow-up, prohibitive cost, injection hesitancy) driving primary non-adherence more frequently than insurance denials.
The CDC's analysis confirmed that publicly insured patients face systematic disadvantages, with Medicaid beneficiaries less likely to be prescribed respiratory biologics compared to their commercially insured counterparts, despite higher disease burden. A 2019 mixed-methods study across six U.S. specialty clinics found that 45% of patients ranked out-of-pocket costs as the most important factor in biologic selection, overwhelming considerations of administration.
mode (28%) or time to efficacy (15%). Specialist access represents an additional constraint, as the uninsured or under-insured receive limited referrals to allergy-immunology specialists, who prescribe the overwhelming majority of allergen immunotherapy and monoclonal antibodies. Geographic disparities compound these barriers, as specialized treatment centers concentrate in urban academic settings, leaving rural and underserved populations with limited access to advanced immunotherapy options. Racial and ethnic disparities further limit market penetration. A multicenter EHR-based study documented that Black and Latinx adults with allergic rhinitis are 60% and 20% less likely, respectively, than non-Hispanic White adults to initiate subcutaneous immunotherapy (SCIT). Among Medicaid recipients, SCIT injection adherence varies significantly by payer status—Medicaid patients miss an average of 34.2% of injections, compared to 24.4% for Medicare and 19.9% for commercially insured patients. These disparities reflect broader structural barriers, including transportation challenges, inability to take time from work or school for frequent injections, and inequitable referral patterns.
Regulatory Hurdles
The immunotherapy market faces substantial regulatory complexity that increases development costs, extends timelines, and creates compliance burdens across jurisdictions. The FDA's Risk Evaluation and Mitigation Strategies (REMS) program exemplifies these challenges—while the agency eliminated REMS requirements for CAR-T cell therapies in June 2025 due to accumulated clinical experience, this decision followed years of mandatory certification requirements that hospitals and clinics maintain on-site immediate access to tocilizumab and specialized staff training. For allergy and asthma biologics, REMS requirements have historically mandated healthcare setting administration, restricting patient convenience and increasing treatment costs. The FDA's Complete Response Letter (CRL) process creates development uncertainty and market entry delays. In October 2023, ImmunityBio received a CRL for its IL-15 superagonist N-803, requiring resubmission and extending the PDUFA date to April 2024, demonstrating how regulatory feedback can delay market access by 6-12 months or longer. The FDA's July 2025 initiative to publish historical CRLs for drug and biologic product applications reflects ongoing transparency efforts regarding regulatory barriers, with published CRLs revealing manufacturing deficiencies, clinical data insufficiencies, and safety concerns that require extensive remediation.
Medicare coverage limitations present additional regulatory constraints. The Centers for Medicare & Medicaid Services (CMS) National Coverage Determination explicitly excludes sublingual immunotherapy (SLIT) from coverage, stating that "antigens are covered only if they are administered by injection". This policy, maintained as of July 2020, limits patient access to SLIT despite its established efficacy in European markets and potential advantages for patient adherence. The 2024 Medicare Part D structure permits tiering exceptions for specialty drugs, but plans may maintain separate tiers for "high cost and unique genomic and bio-tech products," with restrictions on moving drugs from specialty to non-specialty tiers. Transatlantic regulatory divergence creates market fragmentation. The European Medicines Agency (EMA) and FDA maintain distinct pharmacovigilance requirements, with EudraVigilance requiring different safety data formatting than FDA's FAERS system, and Risk Management Plans (RMPs) versus REMS creating "compliance costs that involve following different regulatory landscapes, duplicate costs and resource allocations for the approval of the same product". These discrepancies result in market delays and regulatory uncertainty that hamper global innovation and technology transfer.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 106 companies operating in the North America & Europe Immuno-Therapy Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Eli Lilly is a research-based, vertically integrated pharmaceutical manufacturer that discovers, develops, manufactures and markets prescription medicines in a single reported business segment: human pharmaceutical products. Its commercial identity has been transformed since 2022 by the incretin class: tirzepatide, a dual GIP/GLP-1 receptor agonist, and from April 2026 orforglipron, an orally bioavailable non-peptide GLP-1 agonist. These assets have made Lilly the dominant player in the fastest-growing therapeutic category in pharmaceutical history, and have funded a step-change in capital deployment — more than $50 billion of announced U.S. manufacturing investment since 2020, $13.3 billion of FY2025 R&D spend, and more than a dozen acquisitions in 2026 alone. Around that core the company sustains four other franchises — oncology, immunology, neuroscience and legacy diabetes — and a direct-to-patient platform, LillyDirect. Lilly's central strategic bet is that obesity becomes a chronic-care category of unprecedented scale, and that it can own the supply, the pricing architecture and the next three generations of molecules within it. Eli Lilly and Company is, as of September 2026, the largest pharmaceutical company in the world by market capitalisation and the fastest-growing large-cap drug manufacturer by revenue. The company crossed the $1 trillion market-capitalisation threshold during 2025 — the first biopharmaceutical company ever to do so — on the strength of a single molecule, tirzepatide, commercialised under two brands (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnoea) that together generated $36.5 billion of revenue in FY2025. In April 2026 the company added the first small-molecule oral GLP-1 receptor agonist approved for obesity, Foundayo (orforglipron), to that franchise. --- ### The company's own characterisation Lilly describes itself in the FY2025 Form 10-K as a company that discovers, develops, manufactures and markets products in a single business segment — human pharmaceutical products — and states that most of the products it sells today were discovered or developed by its own scientists, with long-term success depending on the ability to continually discover or acquire, develop and commercialise innovative medicines. It manufactures and distributes through facilities in the United States (including Puerto Rico) and in Europe and Asia, and sells in approximately 105 countries. In its standard corporate boilerplate (Q2 2026 earnings release) Lilly positions itself as "a medicine company turning science into healing," with a 150-year history and scientific focus areas described as redefining diabetes care; treating obesity and curtailing its long-term complications; advancing the fight against Alzheimer's disease; addressing immune system disorders; and transforming difficult-to-treat cancers into manageable diseases. ### Independent characterisation Lilly is best understood today as three overlapping businesses operating under one P&L: **(a) The incretin platform (roughly 74% of FY2025 revenue).** Tirzepatide (Mounjaro + Zepbound) alone contributed $36.5 billion in FY2025, growing to a first-half 2026 run-rate of $27.7 billion across the two brands. Adding orforglipron (Foundayo, $98 million in its first partial quarter), legacy insulins, Trulicity and the Boehringer-partnered SGLT2/DPP-4 products, cardiometabolic health accounted for approximately $48.2 billion of FY2025 revenue. This is a volume business with unusually strong operating leverage: gross margin on the incretin portfolio has driven consolidated gross margin from 75.4% in FY2021 to 86.3% (non-GAAP) in Q2 2026, even as realised prices fell 13% year-on-year in that quarter. **(b) The diversified specialty portfolio (roughly 24% of FY2025 revenue).** Oncology ($9.4 billion), immunology ($5.2 billion) and neuroscience ($1.4 billion) constitute a conventional branded-pharma business with a normal mix of growth assets (Jaypirca, Ebglyss, Omvoh, Kisunla, Inluriyo) and mature or declining ones (Cyramza, Emgality, Taltz, Olumiant). Management has explicitly flagged this cluster as its diversification hedge: key-product revenue in immunology, oncology and neuroscience grew 121% year-on-year in Q2 2026. **(c) A capital-deployment engine.** With $16.8 billion of FY2025 operating cash flow rising to a $28.1 billion trailing-twelve-month figure at June 2026, Lilly has become one of the most acquisitive companies in the sector — at least thirteen acquisitions announced in 2026 through August — and the largest single builder of pharmaceutical manufacturing capacity in U.S. history. ### Revenue model and value-chain position Lilly's revenue is overwhelmingly product revenue. Approximately 93.5% of FY2025 revenue was product sales, with the balance (approximately $4.2 billion) collaboration and other revenue, principally from the Boehringer Ingelheim diabetes alliance, the Incyte relationship on Olumiant, royalty streams and sales-based milestones. There is no subscription revenue; "service" revenue is immaterial. The company occupies an unusually deep position in its value chain for a modern large-cap pharma: it manufactures its own active pharmaceutical ingredients, fills and finishes its own injectable devices, and, since January 2024, sells directly to patients through LillyDirect, bypassing parts of the traditional wholesaler-pharmacy-PBM chain for self-pay volumes. **Customer types and end-markets.** The direct customers are wholesalers and distributors (McKesson, Cencora, Cardinal Health in the U.S.), retail and specialty pharmacy chains, hospital systems, government purchasers (Medicare Part D plans, Medicaid programs, the Veterans Health Administration, and from 2026 the TrumpRx platform), managed-care organisations and pharmacy benefit managers, and — increasingly — patients paying cash through LillyDirect and affiliated telehealth partners. End-markets are obesity and metabolic disease, type 2 diabetes, oncology, immunology/inflammation, neurodegeneration and pain.
Merck KGaA is a 358-year-old, family-controlled, diversified science and technology group generating EUR 21.1 billion of net sales (FY2025) across three complementary business sectors: Life Science (42% of sales; a top-three global supplier of research tools, bioprocessing consumables and testing services, known in North America as MilliporeSigma), Healthcare (41%; a specialty pharmaceutical company with established franchises in oncology, multiple sclerosis, fertility and cardiometabolic care plus a new rare-tumour franchise acquired via SpringWorks), and Electronics (17%; a now pure-play semiconductor and optronics materials, equipment and metrology supplier exposed to AI-driven advanced nodes). The group operates at a ~29% EBITDA pre margin with net financial debt of ~1.4x EBITDA pre. Its investment case rests on three growth drivers — Process Solutions, Rare Diseases and Semiconductor Solutions — which management expects to generate up to 80% of medium-term growth, now being reinforced by the pending US$11.3 billion Bio-Techne acquisition. --- ### Company's own description (paraphrased from AR 2025) The company describes itself as a science and technology company guided by the vision "Sparking Discovery, Elevating Humanity," working across Life Science, Healthcare and Electronics to create value for customers and patients. The founding family, now in its 13th generation, remains majority owner through the KGaA structure. Financial reporting presents three business sectors plus Corporate and Other, and five regions (Europe, North America, Asia-Pacific, Latin America, Middle East and Africa). The company's own boilerplate (2026 press releases) characterises its activity as accelerating drug development and manufacturing, discovering treatments for challenging diseases, and enabling "the intelligence of devices." ### Independent characterisation Merck KGaA is best understood as a conglomerate of three high-margin specialty businesses with distinct economic cycles: 1. **Life Science** is a consumables-heavy, recurring-revenue tools franchise. Roughly 42% of sector sales (Process Solutions) are "embedded" in customers' validated biomanufacturing processes (filters, chromatography resins, single-use assemblies, cell culture media, excipients), creating high switching costs because regulatory re-validation is required to change suppliers. The research catalogue business (legacy Sigma-Aldrich; now Discovery Solutions) is a broad, transactional, e-commerce-led reagent business with more than 300,000 products. Services (testing, CDMO for ADCs/viral vectors/HPAPIs) are smaller and lumpier. 2. **Healthcare** is a mid-sized specialty pharma business whose cash generation rests disproportionately on mature, off-patent or near-off-patent brands (Glucophage, Concor, Euthyrox, Erbitux, Rebif, Gonal-f) and on Mavenclad, which began losing US exclusivity in 2026. The SpringWorks acquisition (July 2025) created a Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly, pimicotinib) intended to offset these erosions. Historically, internal R&D productivity has been weak (late-stage failures of evobrutinib and xevinapant in 2023–2024). 3. **Electronics** is a materials-and-process-solutions supplier to semiconductor fabs (logic, memory, advanced packaging) and display panel makers. Following the Versum Materials (2019) and AZ Electronic Materials (2014) acquisitions and the 2025 divestment of Surface Solutions (pigments), it is positioned as a pure-play electronics business with 72% of sector sales in Asia-Pacific. ### Revenue model mix The company does not disclose a product/service/subscription/licensing percentage split. Analyst view: product sales (consumables, materials and medicines) constitute the overwhelming majority (>90%) of group revenue; this is an estimate and is flagged as such. ### Value-chain position and customers Regional mix of sector sales (AR 2025): Life Science 71% Europe + North America, 28% Asia-Pacific + Latin America; Healthcare 54% Europe + North America, 39% Asia-Pacific + Latin America; Electronics 72% Asia-Pacific, 26% Europe + North America.
24 interactive charts drawn from the North America & Europe Immuno-Therapy Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
North America & Europe Immuno-Therapy Market By End User
North America & Europe Immuno-Therapy Market By Age Group
North America & Europe Immuno-Therapy Market By Route Of Administration
North America & Europe Immuno-Therapy Market By Atopic Diseases
North America & Europe Immuno-Therapy Market By Respiratory Allergies
North America & Europe Immuno-Therapy Market By Application
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
